|   In the News

Novartis buys a new gene therapy for vision loss, and this is one preclinical venture that didn’t come cheap

Cyrus Mozayeni got excited when he began to explore the academic work of Ehud Isacoff and John G. Flannery at UC Berkeley.

Read more.


  |  

Negotiating 101: Advice From The Trenches

In a recent blog post, I walked through my tips for reading your adversaries’ body language while maintaining your own poker face throughout negotiations.

In this second post, I’ll share practical tactics for gaining leverage and using it wisely. Women of biotech, there’s also a special section for you – so read on!

By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Scorpion Therapeutics debuts with $108M to ‘put the sting in cancer’

When Gary Glick, Ph.D. left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.” Scorpion Therapeutics was born.

Read more.


  |   From the Trenches

Negotiating 101: Advice From The Trenches

It’s back-to-school season, and that puts me in the frame of mind to share some of the most important lessons I’ve learned in a long career focusing on one of the most daunting pillars of the biopharma BD world: the negotiation.

By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Longwood, Atlas Venture inject $52M into cell therapy startup

The drug industry has funneled billions of dollars into cell therapies over the last several years. But there may be something new on the horizon, and a new Cambridge startup is angling to be at the forefront.

Read more.